Inventor · disambiguated record
Fabrizio Giordanetto
Also filed as: GIORDANETTO FABRIZIO
11 granted patents·35 pending applications·72 citations·filing 2005–2023
87Inventor score
Top patents by PatentIndex Score
46 records- 0196US10934302B1SHP2 phosphatase inhibitors and methods of use thereofRELAY THERAPEUTICS INC·Filed 2020·Granted Mar 2, 2021·44 cites·7 claims
- 0291US12084447B2SHP2 phosphatase inhibitors and methods of use thereofRELAY THERAPEUTICS INC·Filed 2020·Granted Sep 10, 2024·2 cites·20 claims
- 0388US12219327B2Substituted isoindolines as PI3K-alpha inhibitorsRELAY THERAPEUTICS INC·Filed 2023·Granted Feb 4, 2025·1 cites·6 claims
- 0486US11701354B2Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitorsRELAY THERAPEUTICS INC·Filed 2018·Granted Jul 18, 2023·3 cites·40 claims
- 0586US7723331B2Thienopyrimidine compounds and uses thereofASTRAZENECA AB·Filed 2007·Granted May 25, 2010·11 cites·13 claims
- 0685US11591336B2Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitorsRELAY THERAPEUTICS INC·Filed 2018·Granted Feb 28, 2023·3 cites·54 claims
- 0784US11529347B2SHP2 phosphatase inhibitors and methods of use thereofRELAY THERAPEUTICS INC·Filed 2017·Granted Dec 20, 2022·4 cites·8 claims
- 0883US11780845B2FGFR inhibitors and methods of use thereofRELAY THERAPEUTICS INC·Filed 2023·Granted Oct 10, 2023·1 cites·2 claims
- 0981US11629145B2SHP2 phosphatase inhibitors and methods of use thereofRELAY THERAPEUTICS INC·Filed 2017·Granted Apr 18, 2023·3 cites·18 claims
- 1078US12331056B2SHP2 phosphatase inhibitors and methods of use thereofRELAY THERAPEUTICS INC·Filed 2022·Granted Jun 17, 2025·0 cites·21 claims
- 1165US2022315586A1Shp2 phosphatase inhibitors and methods of use thereofRELAY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1258US2008045494A1Pyridine Analogues VIASTRAZENECA AB·Filed 2007·Application pending·0 cites
- 1357US2011059981A9New Pyridine Analogues VASTRAZENECA AB·Filed 2007·Application pending·0 cites
- 1456US2025090540A1Pi3k-alpha inhibitors and methods of use thereofRELAY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1554US2025270198A1Pyridone compounds as trpa1 inhibitorsDE SHAW RES LLC·Filed 2023·Application pending·0 cites
- 1654US2010137277A1Pyridine compounds and their use as p2y12 antagonistsASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 1754US2008171732A1New Pyridine Analogues IX 519ASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 1853US2025136587A1N3-substituted uracil compounds as trpa1 inhibitorsDE SHAW RES LLC·Filed 2023·Application pending·0 cites
- 1953US2025154139A1Pyridazinone compounds as trpa1 inhibitorsDE SHAW RES LLC·Filed 2023·Application pending·0 cites
- 2053US2009286834A1Pyridine Analogues VIASTRAZENECA AB·Filed 2007·Application pending·0 cites
- 2153US2008039437A1New Pyridine Analogues IIIASTRAZENECA AB·Filed 2007·Application pending·0 cites
- 2253US2010069350A1New Pyridine Analogues IIIASTRAZENECA AB·Filed 2007·Application pending·0 cites
- 2352US2024391926A1SPIROINDOLINONE COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERSDE SHAW RES LLC·Filed 2022·Application pending·0 cites
- 2452US2008032992A1New Pyridine Analogues VASTRAZENECA AB·Filed 2007·Application pending·0 cites
- 2551US2024368078A1ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERSDE SHAW RES LLC·Filed 2022·Application pending·0 cites
- 2650US2025154154A1Src inhibitors and uses thereofRELAY BINNEY STREET 2ND FLOOR·Filed 2021·Application pending·0 cites
- 2749US2008200448A1New Pyridine Analogues VIII 518ASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 2849US2008176827A1New Pyridine Analogues VII 543ASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 2949US2020392161A1Shp2 phosphatase inhibitors and methods of use thereofRELAY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3048US2022144840A1Heterocyclic compounds and their use in the treatment of amyloid-related diseasesDE SHAW RES LLC·Filed 2020·Application pending·0 cites
- 3148US2023373952A1LACTAM COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERSDE SHAW RES LLC·Filed 2021·Application pending·0 cites
- 3246US2023131535A1ARYLMETHYLENE AROMATIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERSDE SHAW RES LLC·Filed 2020·Application pending·0 cites
- 3345US2009018166A1New Pyridine Analogues X 161ASTRAZENECA AB·Filed 2008·Application pending·0 cites
- 3444US2023023559A1Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockersDE SHAW RES LLC·Filed 2020·Application pending·0 cites
- 3544US2023049231A1ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERSDE SHAW RES LLC·Filed 2020·Application pending·0 cites
- 3644US2022411367A1Arylmethylene heterocyclic compounds as kv1.3 potassium shaker channel blockersDE SHAW RES LLC·Filed 2020·Application pending·0 cites
- 3744US2023026611A1ARYL HETEROCYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERSDE SHAW RES LLC·Filed 2020·Application pending·0 cites
- 3844US2023040182A1ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERSDE SHAW RES LLC·Filed 2020·Application pending·0 cites
- 3943US2008221107A1Therapeutic AgentsASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 4041US2008312208A1Pyridine AnaloguesASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 4140US12138263B2Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereofRELAY THERAPEUTICS INC·Filed 2019·Granted Nov 12, 2024·0 cites·16 claims
- 4240US2009227555A2Novel Pyridine CompoundsASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 4339US2007185079A1Therapeutic agents IASTRAZENECA AB·Filed 2005·Application pending·0 cites
- 4439US2020308165A1Compounds as Ras Inhibitors and Use ThereofDE SHAW RES LLC·Filed 2018·Application pending·0 cites
- 4536US2008306055A1Heterocyclic Mchr1 Antagonists And Their Use In TherapyASTRAZENECA AB·Filed 2005·Application pending·0 cites
- 4635US2008300232A1N-Piperidine Derivatives as Ccr3 ModulatorsASTRAZENECA AB·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Fabrizio Giordanetto files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →